Kodiak(KOD) - 2025 Q4 - Annual Results

Financial Performance - Kodiak Sciences reported a net loss of $56.7 million for Q4 2025, compared to a net loss of $44.1 million in Q4 2024, with a loss per share of $1.04[14]. - The net loss for the year ended December 31, 2025, was $230.0 million, compared to a net loss of $176.2 million in 2024[35]. - Cash and cash equivalents as of December 31, 2025, were $209.9 million, an increase from $168.1 million in 2024, indicating improved liquidity[36]. - Total assets increased to $351.5 million as of December 31, 2025, compared to $335.6 million in 2024, reflecting growth in the company's financial position[36]. - Kodiak's accumulated deficit reached $1.56 billion as of December 31, 2025, up from $1.33 billion in 2024, highlighting ongoing investment in R&D[36]. Research and Development - Research and development (R&D) expenses for Q4 2025 were $45.5 million, up from $31.8 million in Q4 2024, driven by increased clinical activities[15]. - R&D expenses for the full year 2025 totaled $182.4 million, compared to $126.1 million in 2024, reflecting increased clinical activities[16]. - Research and development expenses for the year ended December 31, 2025, were $182.4 million, up from $126.1 million in 2024, reflecting increased investment in clinical programs[35]. - KSI-501 is designed to provide high immediacy and durability in treating retinal vascular diseases, with a focus on addressing unmet needs in the market[27]. Clinical Trials and Studies - The GLOW2 Phase 3 study showed that 62.5% of Zenkuda-treated patients achieved a ≥2-step improvement in diabetic retinopathy severity score (DRSS), compared to 3.3% in the sham group[9]. - Zenkuda demonstrated an 85% risk reduction in developing sight-threatening complications, with 2.4% of Zenkuda patients versus 15.8% of sham patients experiencing such complications[9]. - The Phase 3 DAYBREAK study for Zenkuda and KSI-501 aims to demonstrate non-inferiority in visual acuity gains compared to aflibercept, with topline data expected in Q3 2026[29][30]. - The company is advancing KSI-101 in Phase 3 studies, with topline results expected in Q4 2026 and Q2 2027[4]. Equity and Funding - Kodiak completed an equity offering in December 2025, issuing 8 million shares at $23.00 per share, resulting in net proceeds of $173.0 million[10]. Technology and Innovation - Kodiak's digital health initiatives include the development of an AI-powered wearable headset for retina care, reflecting a long-term strategy to integrate therapeutics and vision technologies[6]. - The company is exploring the development of an AI-powered wearable headset for applications in retina care, indicating a diversification of its technology portfolio[33]. - Kodiak aims to accelerate the timeline for a multi-indication BLA submission for Zenkuda, with expectations for future regulatory applications[33]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2025 were $12.0 million, down from $14.4 million in Q4 2024, aided by sublease income[17].